Zelira Therapeutics Ltd ZLDAF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.47
- Day Range
- $0.47–0.48
- 52-Week Range
- $0.47–1.65
- Bid/Ask
- $0.40 / $0.50
- Market Cap
- $5.45 Mil
- Volume/Avg
- 2,113 / 1,489
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 28.40
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Zelira Therapeutics Ltd is a biotechnology company focused on developing a range of cannabinoid-based formulations for the treatment of various medical conditions in Australia. The company is involved in a human clinical trial program focused on insomnia, autism, and eczema; and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 8
- Website
- https://www.zeliratx.com
Valuation
|
Metric
|
ZLDAF
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 28.40 |
Price/Cash Flow | — |
Price/Earnings
ZLDAF
Financial Strength
|
Metric
|
ZLDAF
|
|---|---|
Quick Ratio | 0.15 |
Current Ratio | 0.43 |
Interest Coverage | −143.46 |
Quick Ratio
ZLDAF
Profitability
|
Metric
|
ZLDAF
|
|---|---|
Return on Assets (Normalized) | −23.94% |
Return on Equity (Normalized) | −28.02% |
Return on Invested Capital (Normalized) | −25.49% |
Return on Assets
ZLDAF
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Mqctglflsx | Kvsj | $562.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Ztqtrdxjh | Ygbcprj | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Xffnxvp | Ybnmrr | $99.5 Bil | |
MRNA
| Moderna Inc | Htlkhzs | Mfm | $38.8 Bil | |
ARGX
| argenx SE ADR | Rxykrnth | Tgt | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Rprtfsgs | Vbjxy | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Jkrrdkg | Xzjnwml | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Twptslhgv | Scqfvr | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Pbnxnhvn | Mrvwwcd | $12.5 Bil | |
INCY
| Incyte Corp | Jhhmntpfl | Qmpcsy | $11.6 Bil |